Effect and mechanism of long non-coding RNA ZEB2-AS1 in the occurrence and development of colon cancer

Xu Guo; Yuanming Jing; Haizhou Lou; Qiaonv Lou; Xu Guo; Yuanming Jing; Haizhou Lou; Qiaonv Lou

doi:10.3934/mbe.2019408

Mathematical Biosciences and Engineering

2019, Volume 16, Issue 6: 8109-8120. doi: 10.3934/mbe.2019408

Previous Article Next Article

Research article Special Issues

Effect and mechanism of long non-coding RNA ZEB2-AS1 in the occurrence and development of colon cancer

1.
Department of Anorectal Surgery, Dalian Municipal Central Hospital, Dalian, Liaoning 116033, China
2.
Department of General Surgery, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine)
3.
Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China
4.
Department of Orthopedics, The Sixth People's Hospital of Cixi, Ningbo 315300, China

Received: 20 February 2019 Accepted: 10 July 2019 Published: 06 September 2019

ObjectiveClarify the expression changes, biological functions and related mechanisms of long non-coding RNA (lncRNA) ZEB2-AS1 in colon cancer tissues.

Methods The expression levels of ZEB2-AS1 in colon cancer tissues and adjacent tissues were detected by qRT-PCR and in situ hybridization methods. Cell biology experiments were performed to detect the proliferation, migration and apoptosis of colon cancer cells when the level of ZEB2-AS1 was overexpression or silencing. Then, Western blot was performed to analyze the effect of ZEB2-AS1 on the expression levels of β-catenin protein and related genes in the signal pathway.

Results We found that the expression level of ZEB2-AS1 in colon cancer tissues was significantly up-regulated compared with that in adjacent normal tissues. In colon cancer cell line of HCT8, overexpression of ZEB2-AS1 could promote cell proliferation and migration, while silencing ZEB2-AS1 would enhance cell apoptosis and inhibit proliferation. Study on the mechanism of ZEB2-AS1 showed that it could promote the expression of β-catenin, activate downstream genes to be transcribed and promote the occurrence and development of tumors.

Conclusion ZEB2-AS1 could promote colon cancer cell proliferation and inhibit apoptosis to promote the progression of colon cancer by upregulating the expression of β-catenin protein. ZEB2-AS1 may be a useful new target for treating colon cancer patients.
- long non-coding RNA,
- ZEB2-AS1,
- colon cancer,
- β-catenin protein
Citation: Xu Guo, Yuanming Jing, Haizhou Lou, Qiaonv Lou. Effect and mechanism of long non-coding RNA ZEB2-AS1 in the occurrence and development of colon cancer[J]. Mathematical Biosciences and Engineering, 2019, 16(6): 8109-8120. doi: 10.3934/mbe.2019408

Related Papers:

Abstract

ObjectiveClarify the expression changes, biological functions and related mechanisms of long non-coding RNA (lncRNA) ZEB2-AS1 in colon cancer tissues.

Methods The expression levels of ZEB2-AS1 in colon cancer tissues and adjacent tissues were detected by qRT-PCR and in situ hybridization methods. Cell biology experiments were performed to detect the proliferation, migration and apoptosis of colon cancer cells when the level of ZEB2-AS1 was overexpression or silencing. Then, Western blot was performed to analyze the effect of ZEB2-AS1 on the expression levels of β-catenin protein and related genes in the signal pathway.

Results We found that the expression level of ZEB2-AS1 in colon cancer tissues was significantly up-regulated compared with that in adjacent normal tissues. In colon cancer cell line of HCT8, overexpression of ZEB2-AS1 could promote cell proliferation and migration, while silencing ZEB2-AS1 would enhance cell apoptosis and inhibit proliferation. Study on the mechanism of ZEB2-AS1 showed that it could promote the expression of β-catenin, activate downstream genes to be transcribed and promote the occurrence and development of tumors.

Conclusion ZEB2-AS1 could promote colon cancer cell proliferation and inhibit apoptosis to promote the progression of colon cancer by upregulating the expression of β-catenin protein. ZEB2-AS1 may be a useful new target for treating colon cancer patients.

References

[1]	Y. Yin, J. Zhong, S. W. Li, et al., TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer, Oncotarget,7 (2016), 86755-86765.
[2]	K. Liu, H. Yao, S. Lei, et al., The miR-124-p63 feedback loop modulates colorectal cancer growth, Oncotarget,8 (2017), 29101-29115.
[3]	M. Yue, J. L. Charles Richard and Y. Ogawa, Dynamic interplay and function of multiple noncoding genes governing X chromosome inactivation, Biochim. Biophys. Acta,1859 (2016), 112-120.
[4]	A. A. Butler, W. M. Webb and F. D. Lubin, Regulatory RNAs and control of epigenetic mechanisms: expectations for cognition and cognitive dysfunction, Epigenomics,8 (2016), 135-151.
[5]	C. Kanduri, Long noncoding RNAs: Lessons from genomic imprinting, Biochim. Biophys. Acta,1859 (2016), 102-111.
[6]	C. Tordonato, P. P. Di Fiore and F. Nicassio, The role of non-coding RNAs in the regulation of stem cells and progenitors in the normal mammary gland and in breast tumors, Front Genet.,6 (2015), 72.
[7]	J. R. Prensner, M. K. Iyer, O. A. Balbin, et al., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression, Nat. Biotechnol.,29 (2011), 742-749.
[8]	W. Li, J. Zheng, J. Deng, et al., Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells, Gastroenterology,146 (2014), 1714-1726.e1715.
[9]	R. Chen, G. Wang, Y. Zheng, et al., Long non-coding RNAs in osteosarcoma, Oncotarget,8 (2017), 20462-20475.
[10]	Z. Yang, X. Li, Y. Yang, et al., Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma, Cell Death Dis.,7 (2016), e2389.
[11]	K. P. Zhu, X. L. Ma and C. L. Zhang, LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis, Mol. Ther.,25 (2017), 2383-2393.
[12]	B. Wang, Y. Su, Q. Yang, et al., Overexpression of Long Non-Coding RNA HOTAIR Promotes Tumor Growth and Metastasis in Human Osteosarcoma, Mol. Cells,38 (2015), 432-440.
[13]	Y. Guo, Y. Hu, M. Hu, et al., Long non-coding RNA ZEB2-AS1 promotes proliferation and inhibits apoptosis in human lung cancer cells, Oncol. Lett.,15 (2018), 5220-5226.
[14]	H. Gao, N. Gong, Z. Ma, et al., LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis, Int. J. Biol. Macromol.,116 (2018), 545-551.
[15]	P. Diao, H. Ge, Y. Song, et al., Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma, J. Cell. Mol. Med.,23 (2019), 4269-4280.
[16]	X. Shi, J. Li, L. Ma, et al., Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia, Oncol. Lett.,17 (2019), 4935-4947.
[17]	C. Xu, H. Cui, H. Li, et al., Long non-coding RNA ZEB2-AS1 expression is associated with disease progression and predicts outcome in gastric cancer patients, J. Buon.,24 (2019), 663-671.
[18]	S. Xu, D. Kong, Q. Chen, et al., Oncogenic long noncoding RNA landscape in breast cancer, Mol. Cancer,16 (2017), 129.
[19]	G. Zhang, H. Li, R. Sun, et al., Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2, J. Cell. Mol. Med.,23 (2019), 3271-3279.
[20]	F. Wang, W. Zhu, R. Yang, et al., LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/beta-catenin pathway, Mol. Cell. Biochem.,456 (2019), 73-83.
[21]	C. He, W. Yang, J. Yang, et al., Long noncoding RNA MEG3 negatively regulates proliferation and angiogenesis in vascular endothelial cells, DNA Cell Biol.,36 (2017), 475-481.
[22]	L. E. Dow, K. P. O'Rourke, J. Simon, et al., APC restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer, Cell,161 (2015), 1539-1552.
[23]	J. N. Anastas and R. T. Moon, WNT signalling pathways as therapeutic targets in cancer, Nat. Rev. Cancer,13 (2013), 11-26.
[24]	J. Li, B. Yu, P. Deng, et al., KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/beta-catenin signalling, Nat. Commun.,8 (2017), 15146.
[25]	P. Zhu, Y. Wang, G. Huang, et al., lnc-beta-Catm elicits EZH2-dependent beta-catenin stabilization and sustains liver CSC self-renewal, Nat. Struct. Mol. Biol.,23 (2016), 631-639.

Reader Comments

Your name:*

Email:*
© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)